{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:44:21Z","timestamp":1740159861488,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis Pharmaceutical"},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-075-071"],"award-info":[{"award-number":["MOST 111-2314-B-075-071"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s13318-023-00854-4","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:02:12Z","timestamp":1695711732000},"page":"665-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B\/C and Chronic Kidney Disease: An Open-Label, Phase I Study"],"prefix":"10.1007","volume":"48","author":[{"given":"Chun-Jui","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-8223","authenticated-orcid":false,"given":"Kuang-Chung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"1\u20132","key":"854_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","volume":"286","author":"HA Schmid","year":"2008","unstructured":"Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1\u20132):69\u201374. https:\/\/doi.org\/10.1016\/j.mce.2007.09.006.","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"854_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707\u201316. https:\/\/doi.org\/10.1530\/eje.0.1460707.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"854_CR3","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1210\/jc.2003-031319","volume":"89","author":"RD Murray","year":"2004","unstructured":"Murray RD, Kim K, Ren SG, et\u00a0al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab. 2004;89(6):3027\u201332. https:\/\/doi.org\/10.1210\/jc.2003-031319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"854_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1358\/dot.2013.49.2.1915142","volume":"49","author":"RA Feelders","year":"2013","unstructured":"Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LJ. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc). 2013;49(2):89\u2013103. https:\/\/doi.org\/10.1358\/dot.2013.49.2.1915142.","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"854_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, et\u00a0al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791\u20139. https:\/\/doi.org\/10.1210\/jc.2013-2480.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"854_CR6","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"Petersenn S, Schopohl J, Barkan A, et\u00a0al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781\u20139. https:\/\/doi.org\/10.1210\/jc.2009-2272.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"854_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, et\u00a0al. Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009;94(1):115\u201322. https:\/\/doi.org\/10.1210\/jc.2008-1008.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"854_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, et\u00a0al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366(10):914\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1105743.","journal-title":"N Engl J Med"},{"issue":"5","key":"854_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-11-0367","volume":"19","author":"LK Kvols","year":"2012","unstructured":"Kvols LK, Oberg KE, O\u2019Dorisio TM, et\u00a0al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19(5):657\u201366. https:\/\/doi.org\/10.1530\/ERC-11-0367.","journal-title":"Endocr Relat Cancer"},{"key":"854_CR10","unstructured":"European Medicines Agency: Summary of Product Characteristics: Signifor powder and solvent for suspension for injection. Camberley."},{"key":"854_CR11","unstructured":"Masow J, Riley N. Novartis drug Signifor\u00ae recommended by FDA advisory committee for approval to treat patients with Cushing's disease. Updated November 7, 2022. https:\/\/www.fiercebiotech.com\/biotech\/novartis-drug-signifor%C2%AE-recommended-by-fda-advisory-committee-for-approval-to-treat. Accessed 25 July 2022."},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/DDDT.S29125","volume":"6","author":"G Golor","year":"2012","unstructured":"Golor G, Hu K, Ruffin M, et\u00a0al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Dev Ther. 2012;6:71\u20139. https:\/\/doi.org\/10.2147\/DDDT.S29125.","journal-title":"Drug Des Dev Ther"},{"issue":"3","key":"854_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.clinthera.2012.01.015","volume":"34","author":"S Petersenn","year":"2012","unstructured":"Petersenn S, Hu K, Maldonado M, et\u00a0al. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin Ther. 2012;34(3):677\u201388. https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.015.","journal-title":"Clin Ther"},{"issue":"2","key":"854_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12020-012-9668-1","volume":"42","author":"C Beglinger","year":"2012","unstructured":"Beglinger C, Hu K, Wang Y, et\u00a0al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, phase I study. Endocrine. 2012;42(2):366\u201374. https:\/\/doi.org\/10.1007\/s12020-012-9668-1.","journal-title":"Endocrine"},{"issue":"3","key":"854_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/MJT.0b013e31824c3eb4","volume":"21","author":"M Shenouda","year":"2014","unstructured":"Shenouda M, Maldonado M, Wang Y, et\u00a0al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2014;21(3):164\u201373. https:\/\/doi.org\/10.1097\/MJT.0b013e31824c3eb4.","journal-title":"Am J Ther"},{"issue":"8","key":"854_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.clinthera.2014.06.006","volume":"36","author":"X Chen","year":"2014","unstructured":"Chen X, Shen G, Jiang J, et\u00a0al. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther. 2014;36(8):1196\u2013210. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.006.","journal-title":"Clin Ther"},{"issue":"5","key":"854_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1530\/EJE-11-0773","volume":"166","author":"H Dietrich","year":"2012","unstructured":"Dietrich H, Hu K, Ruffin M, et\u00a0al. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study. Eur J Endocrinol. 2012;166(5):821\u20138. https:\/\/doi.org\/10.1530\/EJE-11-0773.","journal-title":"Eur J Endocrinol"},{"key":"854_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DDDT.S77999","volume":"10","author":"D Cuevas-Ramos","year":"2016","unstructured":"Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with acromegaly. Drug Des Dev Ther. 2016;10:227\u201339. https:\/\/doi.org\/10.2147\/DDDT.S77999.","journal-title":"Drug Des Dev Ther"},{"issue":"4","key":"854_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/0091270011400072","volume":"52","author":"Y Horsmans","year":"2012","unstructured":"Horsmans Y, Hu K, Ruffin M, et\u00a0al. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. J Clin Pharmacol. 2012;52(4):552\u20138. https:\/\/doi.org\/10.1177\/0091270011400072.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"854_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000491708","volume":"140","author":"MH Tsai","year":"2018","unstructured":"Tsai MH, Hsu CY, Lin MY, et\u00a0al. Incidence, prevalence, and duration of chronic kidney disease in Taiwan: results from a community-based screening program of 106,094 individuals. Nephron. 2018;140(3):175\u201384. https:\/\/doi.org\/10.1159\/000491708.","journal-title":"Nephron"},{"issue":"Suppl 9","key":"854_CR21","doi-asserted-by":"publisher","first-page":"J85","DOI":"10.1016\/j.vaccine.2012.10.082","volume":"31","author":"K Hennessey","year":"2013","unstructured":"Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S. Hepatitis B control in the World Health Organization\u2019s Western Pacific Region: targets, strategies, status. Vaccine. 2013;31(Suppl 9):J85-92. https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.082.","journal-title":"Vaccine"},{"issue":"4","key":"854_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342. https:\/\/doi.org\/10.1002\/hep.26141.","journal-title":"Hepatology"},{"key":"854_CR23","unstructured":"CTEP. National Cancer Institute: Common Terminology Criteria for Adverse events (CTCAE). Version 4.0. CTEP. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 8 June 2022."},{"issue":"3","key":"854_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","volume":"103","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014;103(3):458\u201365. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.011.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"854_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2337\/diabetes.48.1.77","volume":"48","author":"U Kumar","year":"1999","unstructured":"Kumar U, Sasi R, Suresh S, et\u00a0al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48(1):77\u201385. https:\/\/doi.org\/10.2337\/diabetes.48.1.77.","journal-title":"Diabetes"},{"issue":"2","key":"854_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1210\/jc.2006-1578","volume":"92","author":"V Singh","year":"2007","unstructured":"Singh V, Brendel MD, Zacharias S, et\u00a0al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673\u201380. https:\/\/doi.org\/10.1210\/jc.2006-1578.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"854_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1210\/endo.141.1.7263","volume":"141","author":"MZ Strowski","year":"2000","unstructured":"Strowski MZ, Parmar RM, Blake AD, Schaeffer JM. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141(1):111\u20137. https:\/\/doi.org\/10.1210\/endo.141.1.7263.","journal-title":"Endocrinology"},{"issue":"10","key":"854_CR28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s0006-2952(99)00010-6","volume":"57","author":"Y Zambre","year":"1999","unstructured":"Zambre Y, Ling Z, Chen MC, et\u00a0al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57(10):1159\u201364. https:\/\/doi.org\/10.1016\/s0006-2952(99)00010-6.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"854_CR29","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446\u201353. https:\/\/doi.org\/10.1210\/jc.2013-1771.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"854_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1677\/joe.1.06082","volume":"187","author":"WH Smith","year":"2005","unstructured":"Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG, Balmforth AJ. Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol. 2005;187(3):379\u201386. https:\/\/doi.org\/10.1677\/joe.1.06082.","journal-title":"J Endocrinol"},{"issue":"1","key":"854_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jcph.213","volume":"54","author":"A Breitschaft","year":"2014","unstructured":"Breitschaft A, Hu K, Darstein C, et\u00a0al. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase I, randomized, Four-Way Crossover Study. J Clin Pharmacol. 2014;54(1):75\u201386. https:\/\/doi.org\/10.1002\/jcph.213.","journal-title":"J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00854-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00854-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00854-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T18:29:24Z","timestamp":1699036164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00854-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00854-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chun-Jui Huang, Chieh-Hua Lu, and Kuang-Chung Shih declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statements"}},{"value":"The trial protocol was approved by the Institutional Review Board of the Tri-Service General Hospital (Approval Number: 098-01-015) on Dec 14, 2009.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants signed a written informed consent form prior to enrollment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization, Kuang-Chung Shih; Data Curation, Chun-Jui Huang; Formal Analysis, Chun-Jui Huang, Chieh-Hua Lu, and Kuang-Chung Shih; Writing\u2014Original Draft Preparation, Chun-Jui Huang, Writing\u2014Review & Editing, Chun-Jui Huang, Chieh-Hua Lu, and Kuang-Chung Shih; all authors provided critical feedback and helped shape the research, analysis and manuscript, as well as provided final approval of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}